Table 1.
Pre-Treatment Epitope-specific, Serum IgE/(kappa + lambda) Test Results for MS Patient and Five Control Subjects
| Myelin Mimotopes | Male MS Patient | Female Control 1 | Female Control 2 | Female Control 3 | Male Control 1 | Male Control 2 |
|---|---|---|---|---|---|---|
| ADARM | 7 | 0 | 0 | 0 | 0 | 0 |
| VTLRI | 26 | 0 | 0 | 1 | 0 | 102 |
| HSYQE | 22 | 0 | 0 | 0 | 0 | 0 |
| RNVRF | 0 | 0 | 0 | 0 | 0 | 0 |
| HSYQE | 22 | 0 | 0 | 0 | 0 | 0 |
| IENLH | 0 | 0 | 0 | 0 | 0 | 0 |
| KTGQF | 0 | 0 | 0 | 0 | 0 | 0 |
| NLHRT | 0 | 0 | 0 | 0 | 0 | 0 |
| KTGQF | 0 | 0 | 0 | 0 | 0 | 0 |
| LHRTF | 1 | 0 | 0 | 0 | 0 | 0 |
| KTGQF | 102 | 0 | 0 | 0 | 0 | 0 |
| HRTFE | 0 | 0 | 0 | 0 | 0 | 0 |
| KTGQF | 0 | 0 | 0 | 0 | 0 | 0 |
Depicted are the dimer test-positive results for the MS patient and correspondingly negative results for the three female and two male control subjects. The MS patient was IgE/(kappa + lambda)-positive against the myelin surface PLP dimer epitopes ADARM–ADARM, the myelin surface MOG VTLRI–HSYQE dimer epitopes and the myelin subsurface MOG HRTFE–KTGQF dimer epitopes.